In the rapidly evolving landscape of pharmaceuticals and biotechnology, the emergence of multimodal drug discovery heralds a transformative era, where innovation and strategic foresight are paramount.
Sponsored by:
Articles
RNA has evolved from a molecular messenger into a powerful and versatile therapeutic tool.
Since monoclonal antibodies (mAbs) were developed and received their first approval, they became indispensable as research tools and biotherapeutic agents.
In the rapidly evolving landscape of pharmaceuticals and biotechnology, the emergence of multimodal drug discovery heralds a transformative era for drug discovery, where innovation and strategic Foresight are paramount.
White Papers
Drug discovery has long followed a core loop: design a molecule, synthesize it, test its biological properties, and analyze the results to inform the next round of design.
Modern drug discovery produces more data than ever, from genomics and chemical screening to imaging and patient datasets
As pharmaceutical innovation rapidly evolves, the complexity of data generated from RNA therapeutics, gene therapies, antibody-drug conjugates (ADCs), and protein degraders necessitates a new approach to digital infrastructure.
Advancements in healthcare diagnostics, emphasizing the need for innovative technologies to improve disease detection and patient outcomes.
Guidelines
Modern drug discovery depends on fast, reliable access to high-quality experimental data. Yet many R&D teams still rely on disconnected systems, manual documentation, or outdated ELNs that cannot keep pace with evolving scientific processes.
Contemporary scientific research reflects a growing focus on complexity and collaboration.